Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) - Catalog

  • Name

    Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

  • Accession Number

    HLB00620823a

  • Acronym

    PEACE

  • Related studies
  • BSI Study IDs

    PEC

  • Is public use dataset

    False

  • Keywords
  • Ingestion Status
    Released
  • Has Study Datasets

    True

  • Has Specimens

    True

  • Specimen ID Type
    Coded
  • Study Website
  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
    NCT00000558
  • Study type
    Clinical Trial
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Adult
  • Interventions

    Drug: angiotensin-converting enzyme inhibitors

  • Study Open Date (Data)

    2009-10-01

  • Study Open Date (Specimens)

    2009-10-01

  • Date materials available

    2008-10-13

  • Last updated

    2008-01-15

  • Study period

    November 1995 - June 2005

  • Study Contacts
  • NHLBI Division

    DCVS

  • Classification
    Heart
  • HIV study classification
    non-HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    0

  • # of Returned Specimens

    0

  • Primary Publication URLs
    15531767
  • Commercial use data restrictions
    No
  • Data restrictions based on area of research
    No
  • Commercial use specimen restrictions
    No
  • Non-genetic use specimen restrictions based on area of use
    Yes
  • Genetic use of specimens allowed?
    Yes
  • Genetic use area of research restrictions
    Yes
  • Specific Consent Restrictions

    Consent restricts use of biospecimens to research related to predictors of coronary heart disease progression.

  • Conditions
    Cardiovascular Diseases
    Coronary Disease
    Heart Diseases
    Myocardial Infarction
    Myocardial Ischemia
  • Objectives

    To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.

  • Background

    Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

  • Participants

    The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

  • Design
  • Conclusions

    In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)

  • Disease classification
  • Publications
  • Mat types
    Plasma
    Serum
    Urine
  • Network

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    Placebo: 4,132

    Active Drug, Trandolapril: 4,158


    Last Modified: March 12, 2025, 9:58 a.m.
  • Age
     PlaceboActive drug, trandolaprilAll
    N%N%N%
    46-50912.20942.261852.23
    51-5561014.7662915.13123914.95
    56-6078118.9073317.63151418.26
    61-6581719.7780319.31162019.54
    66-7079519.2486820.88166320.06
    71-7562115.0362014.91124114.97
    76-803498.453327.986818.21
    >=81681.65791.901471.77

    Last Modified: March 12, 2025, 9:58 a.m.
  • Sex
     PlaceboActive drug, trandolaprilAll
    N%N%N%
    Female70417.0479019.00149418.02
    Male342882.96336881.00679681.98

    Last Modified: March 12, 2025, 9:58 a.m.
  • Race

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. PDF Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types
  • General Freeze/Thaw Status
  • Visits (Vials)

    12 March 2025
     

     

    Serum

    Plasma

    Urine

    Total

    Baseline

    7,359

    19,885

    6,712

    33,956

    Follow-up Visit 1

    55

    68

    35

    158

    Follow-up Visit 2

    1,244

    1,325

    724

    3,293

    Follow-up Visit 3

    701

    745

    388

    1,834

    Follow-up Visit 4

    1,823

    1,973

    1,002

    4,798

    Follow-up Visit 5

    1,017

    1,080

    545

    2,642

    Follow-up Visit 6

    2,820

    2,993

    1,546

    7,359

    Follow-up Visit 7

    1,274

    1,404

    675

    3,353

    Follow-up Visit 8

    2,220

    2,391

    1,232

    5,843

    Follow-up Visit 9

    427

    474

    230

    1,131

    Follow-up Visit 10

    423

    500

    238

    1,161

    Follow-up Visit 11

    110

    134

    57

    301

    Follow-up Visit 12

    29

    32

    18

    79

    Unknown

    1,511

    1,813

    736

    4,060


    Last Modified: March 12, 2025, 9:58 a.m.
  • Visits (Subjects)

    12 March 2025
     

     

    Serum

    Total number of subjects

    Average volume (ml) per subject

    Baseline

    3,701

    0.99

    Follow-up Visit 1

    13

    2.12

    Follow-up Visit 2

    251

    2.48

    Follow-up Visit 3

    141

    2.49

    Follow-up Visit 4

    369

    2.49

    Follow-up Visit 5

    207

    2.49

    Follow-up Visit 6

    571

    2.47

    Follow-up Visit 7

    258

    2.49

    Follow-up Visit 8

    450

    2.48

    Follow-up Visit 9

    86

    2.67

    Follow-up Visit 10

    86

    2.63

    Follow-up Visit 11

    22

    2.50

    Follow-up Visit 12

    6

    2.42

    Unknown

    306

    2.48

     

     

    Plasma

    Total number of subjects

    Average volume (ml) per subject

    Baseline

    3,770

    1.94

    Follow-up Visit 1

    13

    2.50

    Follow-up Visit 2

    251

    2.90

    Follow-up Visit 3

    140

    2.86

    Follow-up Visit 4

    368

    2.89

    Follow-up Visit 5

    208

    2.72

    Follow-up Visit 6

    573

    2.78

    Follow-up Visit 7

    260

    2.88

    Follow-up Visit 8

    450

    2.81

    Follow-up Visit 9

    87

    3.13

    Follow-up Visit 10

    86

    3.24

    Follow-up Visit 11

    22

    3.24

    Follow-up Visit 12

    6

    2.84

    Unknown

    306

    3.13

     

     

    Urine

    Total number of subjects

    Average volume (ml) per subject

    Baseline

    3,367

    11.32

    Follow-up Visit 1

    12

    14.58

    Follow-up Visit 2

    242

    14.96

    Follow-up Visit 3

    130

    14.92

    Follow-up Visit 4

    335

    14.96

    Follow-up Visit 5

    184

    14.81

    Follow-up Visit 6

    516

    14.98

    Follow-up Visit 7

    225

    15.00

    Follow-up Visit 8

    413

    14.92

    Follow-up Visit 9

    77

    14.94

    Follow-up Visit 10

    80

    14.88

    Follow-up Visit 11

    19

    15.00

    Follow-up Visit 12

    6

    15.00

    Unknown

    244

    15.30


    Last Modified: March 12, 2025, 9:58 a.m.